Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. The window will be shut from October 1st, 2026, until 48 hours after the declaration of the un-audited standalone and consolidated financial results for the quarter ending September 30th, 2026. The company will announce the date of the board meeting to approve these results in due course. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Akums Drugs and Pharmaceuticals Ltd has been assigned an ESG rating of '65' for the Financial Year 2025-26 by NSE Sustainability Ratings & Analytics Limited. The rating was voluntarily assigned by NSE Sustainability based on publicly available information, and Akums Drugs did not engage their services for this rating. This disclosure is made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided a link for investors to access the detailed ESG rating report.

Akums Drugs and Pharmaceuticals Limited has informed the exchange that its participation in an Investors/Analysts Meet organized by Antique Stock Broking Limited on August 25, 2026, has been cancelled. The cancellation is due to medical reasons affecting the concerned personnel of the company. This event was scheduled to be held at Trident, Bandra Kurla Complex, Mumbai. The company had previously intimated about this meeting on August 13, 2026.

Akums Drugs and Pharmaceuticals Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, prepared by CRISIL Ratings Limited. The report details the utilization of proceeds from the company's Initial Public Offer (IPO). As per the report, there are no deviations from the objects stated in the prospectus. The total gross proceeds from the IPO were ₹6,800.00 million. Revised offer expenses amounted to ₹378.21 million, resulting in revised net proceeds of ₹6,421.80 million. The filing confirms adherence to SEBI regulations regarding IPO fund utilization.

Akums Drugs and Pharmaceuticals Ltd. reported a robust Q1 FY27 performance with a 13.9% year-on-year revenue growth to ₹1,167 crore. The company's operating profitability and PAT also saw significant increases, driven by its CDMO business. EBITDA rose by 35.4% to ₹175 crore, with margins improving to 15.0%. PAT stood at ₹101 crore, up from ₹65 crore in the prior year, with PAT margins improving to 8.4%. The CDMO segment revenue increased to ₹964 crore, contributing significantly to the overall growth. Management expressed confidence in continued growth and strengthening CDMO leadership.

Akums Drugs and Pharmaceuticals Limited announced its Un-audited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. The Board of Directors approved these results during a meeting held on August 08, 2026. The company also submitted a Statement of Deviation pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The independent auditor's review report was also provided. A tax demand of ₹600.92 million for a prior period block has been noted, with the company filing an appeal.

Akums Drugs' consolidated Q1 FY27 (June quarter) print showed profit after tax of ₹100.98 Cr, up 56.1% YoY from ₹64.69 Cr and up 24.2% QoQ from ₹81.34 Cr, on revenue of ₹1,166.63 Cr, up 13.9% YoY and roughly flat (+0.8%) QoQ. Net margin expanded to 8.44% from 6.16% a year ago and 6.82% last quarter; operating margin (EBITDA/revenue) rose to an estimated ~15.0% from ~12.6% YoY. Neither the current nor the year-ago quarter carried exceptional items, so the growth is on a clean, unadjusted basis. The drivers line up closely with management's May 2026 guidance. CDMO external revenue grew 18.6% YoY to ₹964.21 Cr, ahead of the guided "double-digit volume growth." The API segment's loss narrowed to ₹8.15 Cr from ₹10.65 Cr a year ago and from ₹16.75 Cr last quarter, consistent with management's stated goal to "significantly reduce losses" — though full-year API profitability remains unconfirmed, per management's own earlier caveat. Domestic branded formulations grew 7.3% YoY, broadly tracking the guided IPM-level pace. International branded formulations (exports), however, fell 1.5% YoY to ₹34.55 Cr against a guided double-digit export growth target — a clear miss on that specific line even as the consolidated headline beat. A divergence worth flagging: standalone (parent-only) PAT was almost flat YoY at ₹44.84 Cr (-0.06%) even as standalone revenue grew 18.0% YoY — nearly all of the consolidated profit growth is coming from subsidiaries, not the parent entity. No quarter-specific street consensus could be located; full-year FY27 analyst PAT-growth estimates sit around 15-20%, a pace this quarter's +56% YoY print is running well ahead of, though a single quarter isn't directly comparable to an annual estimate. The board also disclosed a fresh income-tax demand of ₹156.02 Cr for the FY19-25 block period tied to the 2025 search-and-seizure action (company has appealed, deposited ₹4.70 Cr under protest, and maintains no adjustment is needed), and subsequent to quarter-end, subsidiary Pure and Cure Healthcare agreed to acquire Oriflame India's manufacturing business for ₹56 Cr, extending the group into color cosmetics, skincare and wellness. Going into Q2, the watch items are whether exports recover toward the guided double-digit pace after this quarter's decline, whether API segment losses keep narrowing toward full-year profitability, and whether CDMO margins begin moving toward the "high teens" management has guided for the medium term as new international contracts and the ₹300 Cr FY27 capex programme (oral solids expansion, injectables, inorganic moves like Oriflame) ramp up.

Akums Drugs and Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 8, 2026. The primary agenda for this meeting is to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. Additionally, the company stated that the trading window, which is currently closed, will reopen 48 hours after the declaration of these financial results, in compliance with SEBI regulations.

Akums Drugs and Pharmaceuticals Ltd, through its wholly-owned subsidiary Pure and Cure Healthcare Private Limited, has approved the acquisition of Oriflame India Private Limited's manufacturing business for a total consideration of INR 56 Crore. The deal includes two manufacturing plants in Roorkee and Noida, along with a leased warehouse in Noida. This acquisition marks Akums' entry into color cosmetics and expands its presence in skincare and wellness products. The trademark and marketing of Oriflame's products in India are excluded from this transaction. The acquisition is expected to be completed by August 31, 2026, and no prior governmental or regulatory approvals are required.

Akums Drugs and Pharmaceuticals Ltd announced that a penalty of INR 3,59,10,000 imposed on its wholly-owned subsidiary, Maxcure Nutravedics Limited, by the Deputy Commissioner of State Tax, Gujarat, has been set aside. The order was passed by the First Appellate Authority, Ahmedabad, on July 3rd, 2026. The penalty was originally imposed due to an incorrect shipping address entered on an invoice and e-way bill in October 2025. This decision will have no financial impact on Akums Drugs and Pharmaceuticals Ltd.